International Textbook of Diabetes Mellitus, 4th Ed., Chapter 8 – Normal β -Cell Function

References:

1. Chan SJ, Steiner DF: Insulin through the ages: phylogeny of a growth promoting and metabolic regulatory hormone. *American Zoologist* 2000;40:213–222.
2. Pacini G, Mari A: Methods for clinical assessment of insulin sensitivity and beta-cell function. *Best Practice & Research: Clinical Endocrinology & Metabolism* 2003;17:305 – 322.
3. Mari A, Pacini G: Methods for the assessment of β-cell function in vivo. In: Roden M (ed.) *Clinical Method in Diabetes Research: Method and Techniques*. Chichester: John Wiley & Sons, Ltd, 2007, pp. 7 – 26.
4. Ferrannini E, Cobelli C: The kinetics of insulin in man. II. Role of the liver. *Diabetes & Metabolism Review* 1987;3:365 – 397.
5. Eaton RP, Allen RC, Schade DS, et al.: Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. *Journal of Clinical Endocrinology & Metabolism* 1980;51:520 – 528.
6. Van Cauter E, Mestrez F, Sturis J, Polonsky KS: Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. *Diabetes* 1992;41:368 – 377.
7. Hovorka R, Jones RH: How to measure insulin secretion. *Diabetes & Metabolism Review* 1994;10:91 – 117.
8. Volund A: Conversion of insulin units to SI units. *American Journal of Clinical Nutrition* 1993;58:714 – 715.
9. Grodsky GM: A threshold distribution hypothesis for packet storage of insulin and its mathematical modeling. *Journal of Clinical Investigation* 1972;51:2047 – 2059.
10. Bergman RN, Urquhart J: The pilot gland approach to the study of insulin secretory dynamics. *Recent Progress in Hormone Research* 1971;27:583 – 605.
11. Cerasi E, Fick G, Rudemo M: A mathematical model for the glucose induced insulin release in man. *European Journal of Clinical Investigation* 1974;4:267 – 278.
12. Licko V, Silvers A: Open-loop glucose-insulin control with threshold secretory mechanism: analysis of intravenous glucose tolerance tests in man. *Mathematical Biosciences* 1975;27:319 – 332.
13. Toffolo G, Bergman RN, Finegood DT, et al.: Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog. *Diabetes* 1980;29:979 – 990.
14. Toffolo G, De Grandi F, Cobelli C: Estimation of beta-cell sensitivity from intravenous glucose tolerance test C-peptide data. Knowledge of the kinetics avoids errors in modeling the secretion. *Diabetes* 1995;44:845 – 854.

15. Hovorka R, Chassin L, Luzio SD, et al.: Pancreatic beta-cell responsiveness during meal tolerance test: model assessment in normal subjects and subjects with newly diagnosed noninsulin-dependent diabetes mellitus. *Journal of Clinical Endocrinology & Metabolism* 1998;83:744 – 750.
16. Breda E, Cavaghan MK, Toffolo G, et al.: Oral glucose tolerance test minimal model indexes of β-cell function and insulin sensitivity. *Diabetes* 2001;50:150 – 158.
17. Toffolo G, Breda E, Cavaghan MK, et al.: Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. *American Journal of Physiology — Endocrinology and Metabolism* 2001;280:E2 – 10.
18. Cretti A, Lehtovirta M, Bonora E, et al.: Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion. *European Journal of Clinical Investigation* 2001;31:405 – 416.
19. Mari A, Tura A, Gastaldelli A, Ferrannini E: Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. *Diabetes* 2002;51(Suppl 1):S221 – S226.
20. Mari A, Schmitz O, Gastaldelli A, et al.: Meal and oral glucose tests for the assessment of β-cell function: modeling analysis in normal subjects. *American Journal of Physiology — Endocrinology and Metabolism* 2002;283:E1159 – E1166.
21. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. *American Journal of Physiology* 1979;237:E214 – 223.
22. Byrne MM, Sturis J, Polonsky KS: Insulin secretion and clearance during low-dose graded glucose infusion. *American Journal of Physiology* 1995;268:E21 – 27.
23. Natali A, Ribeiro R, Baldi S, et al.: Systemic inhibition of nitric oxide synthesis in non-diabetic individuals produces a significant deterioration in glucose tolerance by increasing insulin clearance and inhibiting insulin secretion. *Diabetologia* 2013;56:1183 – 1191.
24. Godsland IF, Jeffs JA, Johnston DG: Loss of beta cell function as fasting glucose increases in the non-diabetic range. *Diabetologia* 2004;47:1157 – 1166.
25. Natali A, Muscelli E, Mari A, et al.: Insulin sensitivity and beta-cell function in the offspring of type 2 diabetic patients: impact of line of inheritance. *Journal of Clinical Endocrinology and Metabolism* 2010;95:4703 – 4711.
26. Martin BC, Warram JH, Krolewski AS, et al.: Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. *Lancet* 1992;340:925 – 929.
27. Kahn SE, Prigeon RL, McCulloch DK, et al.: Quantification of the relationship between insulin sensitivity and beta-cell function in human

subjects. Evidence for a hyperbolic function. *Diabetes* 1993;42:1663 – 1672.
28. Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. *Journal of Clinical Investigation* 1981;68:1456 – 1467.
29. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. *Diabetologia* 2003;46:3 – 19.
30. Mari A, Tura A, Pacini G, et al.: Relationships between insulin secretion after intravenous and oral glucose administration in subjects with glucose tolerance ranging from normal to overt diabetes. *Diabetic Medicine* 2008;25:671 – 677.
31. Mari A, Tura A, Natali A, et al.: Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance. *Diabetologia* 2010;53:749 – 756.
32. Henquin JC, Nenquin M, Stiernet P, Ahrén B: In vivo and in vitro glucose-induced biphasic insulin secretion in the mouse: pattern and role of cytoplasmic Ca2+ and amplification signals in beta-cells. *Diabetes* 2006;55:441 – 451.
33. Rorsman P, Braun M: Regulation of insulin secretion in human pancreatic islets. *Annual Review of Physiology* 2013;75:155 – 179.
34. Henquin JC: Regulation of insulin secretion: a matter of phase control and amplitude modulation. *Diabetologia* 2009;52:739 – 751.
35. Henquin JC: Triggering and amplifying pathways of regulation of insulin secretion by glucose. *Diabetes* 2000;49:1751 – 1760.
36. Nauck MA, Homberger E, Siegel EG, et al.: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. *Journal of Clinical Endocrinology & Metabolism* 1986;63:492 – 498.
37. Perley MJ, Kipnis DM: Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. *Journal of Clinical Investigation* 1967;46:1954 – 1962.
38. Mari A, Bagger JI, Ferrannini E, et al.: Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes. *PLoS ONE* 2013;8:e73154.
39. Muscelli E, Mari A, Natali A, et al.: Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. *American Journal of Physiology—Endocrinology and Metabolism* 2006;291:E1144–1150.
40. Bagger JI, Knop FK, Lund A, et al.: Impaired regulation of the incretin effect in patients with type 2 diabetes. *Journal of Clinical Endocrinology & Metabolism* 2011;96:737–745.
41. Holst JJ, Gromada J: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. *American Journal of Physiology—Endocrinology and Metabolism* 2004;287:E199 – 206.

42. Drucker DJ: The biology of incretin hormones. *Cell Metabolism* 2006;3:153 – 165.
43. Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. *Gastroenterology* 2007;132:2131–2157.
44. Holst JJ: The physiology of glucagon-like peptide 1. *Physiological Reviews* 2007;87:1409–1439
45. Kjems LL, Holst JJ, Volund A, Madsbad S: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. *Diabetes* 2003; 52:380 – 386.
46. Nauck MA, Heimesaat MM, Orskov C, et al.: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. *Journal of Clinical Investigation* 1993;91: 301 – 307.
47. Muscelli E, Mari A, Casolaro A, et al.: Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. *Diabetes* 2008;57:1340–1348.
48. Tura A, Muscelli E, Gastaldelli A, et al.: Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. *Diabetologia* 2014;57:1199 – 1203.
49. Polonsky KS, Given BD, Van Cauter E: Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. *Journal of Clinical Investigation* 1988;81:442–448.
50. Saad A, Dalla Man C, Nandy DK, et al.: Diurnal pattern to insulin secretion and insulin action in healthy individuals. *Diabetes* 2012;61:2691 – 2700.
51. Berger S, Vongaraya N: Insulin response to ingested protein in diabetes. *Diabetes* 1966;15:303–306.
52. Rabinowitz D, Merimee TJ, Maffezzoli R, Burgess JA: Patterns of hormonal release after glucose, protein, and glucose plus protein.*Lancet* 1966;2:454 – 456.
53. Pallotta JA, Kennedy PJ: Response of plasma insulin and growth hormone to carbohydrate and protein feeding. *Metabolism: Clinical and Experimental* 1968;17:901 – 908.
54. Nuttall FQ, Gannon MC, Wald JL, Ahmed M: Plasma glucose and insulin profiles in normal subjects ingesting diets of varying carbohydrate, fat, and protein content. *Journal of the American College of Nutrition* 1985;4:437 – 450.
55. Karamanlis A, Chaikomin R, Doran S, et al.: Effects of protein on glycemic and incretin responses and gastric emptying after oral glucose in healthy subjects. *American Journal of Clinical Nutrition* 2007;86:1364 – 1368.
56. Carr RD, Larsen MO, Winzell MS, et al.: Incretin and islet hormonal responses to fat and protein ingestion in healthy men. *American Journal of Physiology—Endocrinology and Metabolism* 2008;295:E779 – 784.
57. Schmid R, Schulte-Frohlinde E, Schusdziarra V, et al.: Contribution of postprandial amino acid levels to stimulation of insulin, glucagon, and pancreatic polypeptide in humans. *Pancreas* 1992;7:698 – 704.

58. Calbet JA, MacLean DA: Plasma glucagon and insulin responses depend on the rate of appearance of amino acids after ingestion of different protein solutions in humans. *Journal of Nutrition* 2002;132:2174 – 2182.
59. van Loon LJ, Saris WH, Verhagen H, Wagenmakers AJ: Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *American Journal of Clinical Nutrition* 2000;72:96 – 105.
60. Gannon MC, Nuttall FQ: Amino acid ingestion and glucose metabolism--a review. *IUBMB Life* 2010;62:660–668.
61. Newsholme P, Cruzat V, Arfuso F, Keane K: Nutrient regulation of insulin secretion and action. *Journal of Endocrinology* 2014; 221:R105 – R120.
62. Floyd JC, Jr, Fajans SS, Conn JW, et al.: Stimulation of insulin secretion by amino acids. *Journal of Clinical Investigation* 1966; 45:1487 – 1502.
63. Patterson S, Flatt PR, Brennan L, et al.: Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic beta-cell glucose metabolism and insulin secretion. *Journal of Endocrinology* 2006;189:301–310.
64. Nuttall FQ, Mooradian AD, Gannon MC, et al.: Effect of protein ingestion on the glucose and insulin response to a standardized oral glucose load. *Diabetes Care* 1984;7:465–470.
65. Nilsson M, Holst JJ, Bjorck IM: Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. *American Journal of Clinical Nutrition* 2007;85:996 – 1004.
66. Lan-Pidhainy X, Wolever TM: The hypoglycemic effect of fat and protein is not attenuated by insulin resistance. *American Journal of Clinical Nutrition* 2010;91:98–105.
67. JakubowiczD,FroyO,AhrénB,etal.:Incretin,insulinotropicand glucose-lowering effects of whey protein pre-load in type 2 dia- betes: a randomised clinical trial. *Diabetologia* 2014;57:1807 – 1811.
68. Felber JP, Vannotti A: Effects of fat infusion on glucose tolerance and insulin plasma levels. *Medicina Experimentalis. International Journal of Experimental Medicine* 1964;10:153–156.
69. Pelkonen R, Miettinen TA, Taskinen MR, Nikkila EA: Effect of acute elevation of plasma glycerol, triglyceride and FFA levels on glucose utilization and plasma insulin. *Diabetes* 1968;17:76 – 82.
70. Crespin SR, Greenough WB 3rd, Steinberg D: Stimulation of insulin secretion by long-chain free fatty acids. A direct pancreatic effect. *Journal of Clinical Investigation* 1973;52:1979 – 1984.
71. Amery CM, Nattrass M: Fatty acids and insulin secretion. *Diabetes, Obesity & Metabolism* 2000;2:213 – 221.
72. Balasse EO, Ooms HA: Role of plasma free fatty acids in the control of insulin secretion in man. *Diabetologia* 1973;9:145 – 151.
73. Wuesten O, Balz CH, Bretzel RG, et al.: Effects of oral fat load on insulin output and glucose tolerance in healthy control subjects and obese patients without diabetes. *Diabetes Care* 2005;28:360–365.

74. Manco M, Bertuzzi A, Salinari S, et al.: The ingestion of saturated fatty acid triacylglycerols acutely affects insulin secretion and insulin sensitivity in human subjects. *British Journal of Nutrition* 2004;92:895 – 903.
75. Beysen C, Karpe F, Fielding BA, etal.: Interaction between specific fatty acids, GLP-1 and insulin secretion in humans. *Diabetologia* 2002;45:1533 – 1541.
76. Amery CM, Round RA, Smith JM, Nattrass M: Elevation of plasma fatty acids by ten-hour intralipid infusion has no effect on basal or glucose-stimulated insulin secretion in normal man. *Metabolism: Clinical and Experimental* 2000;49:450–454.
77. Collier G, O'Dea K: The effect of coingestion of fat on the glucose, insulin, and gastric inhibitory polypeptide responses to carbohydrate and protein. *American Journal of Clinical Nutrition* 1983;37:941 – 944.
78. Paolisso G, Gambardella A, Amato L, et al.: Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. *Diabetologia* 1995;38:1295–1299.
79. Boden G, Chen X, Rosner J, Barton M: Effects of a 48-h fat infusion on insulin secretion and glucose utilization. *Diabetes* 1995; 44:1239 – 1242.
80. Carpentier A, Mittelman SD, Lamarche B, et al.: Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. *American Journal of Physiology* 1999; 276:E1055 – 1066.
81. Kashyap S, Belfort R, Gastaldelli A, et al.: A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. *Diabetes* 2003;52:2461 – 2474.
82. Xiao C, Giacca A, Carpentier A, Lewis GF: Differential effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, non-diabetic humans. *Diabetologia* 2006;49:1371 – 1379.
83. Hennes MM, Dua A, Kissebah AH: Effects of free fatty acids and glucose on splanchnic insulin dynamics. *Diabetes* 1997;46: 57–62.
84. Balent B, Goswami G, Goodloe G, et al.: Acute elevation of NEFA causes hyperinsulinemia without effect on insulin secretion rate in healthy human subjects. *Annals of the N Y Academy of Sciences* 2002;967:535 – 543.
85. Sako Y, Grill VE: A 48-hour lipid infusion in the rat time- dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. *Endocrinology* 1990;127:1580 – 1589.
86. Stein DT, Esser V, Stevenson BE, et al.: Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. *Journal of Clinical Investigation* 1996;97:2728 – 2735.
87. Wiesenthal SR, Sandhu H, McCall RH, et al.: Free fatty acids impair hepatic insulin extraction in vivo. *Diabetes* 1999;48:766 – 774.
88. Malaisse WJ, Malaisse-Lagae F: Stimulation of insulin secretion by noncarbohydrate metabolites. *Journal of Laboratory and Clinical Medicine* 1968;72:438 – 448.

89. Mokuda O, Sakamoto Y, Hu HY, et al.: Effects of long chain free fatty acids on glucose-induced insulin secretion in the perfused rat pancreas. *Hormone and Metabolic Research* 1993;25:596 – 597.
90. Zhou YP, Grill V: Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. *Journal of Clinical Endocrinology and Metabolism* 1995;80:1584 – 1590.
91. Stein DT, Stevenson BE, Chester MW, et al.: The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. *Journal of Clinical Investigation* 1997;100:398 – 403.
92. Elks ML:Divergent effects of arachidonate and other free fatty acids on glucose-stimulated insulin release from rat islets. *Cellular and Molecular Biology* 1994;40:761–768.
93. Del Prato S, Leonetti F, Simonson DC, et al.: Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. *Diabetologia* 1994; 37:1025 – 1035.
94. Ward WK, Bolgiano DC, McKnight B, et al.: Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. *Journal of Clinical Investigation* 1984;74:1318–1328.
95. Rabinowitz D, Zierler KL: Forearm metabolism in obesity and its response to intra-arterial insulin. Characterization of insulin resistance and evidence for adaptive hyperinsulinism. *Journal of Clinical Investigation* 1962;41:2173–2181.
96. Clausen JO, Borch-Johnsen K, Ibsen H, et al.: Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and lifestyle factors. *Journal of Clinical Investigation* 1996;98:1195–1209.
97. Ferrannini E, Mari A: Beta cell function and its relation to insulin action in humans: a critical appraisal. *Diabetologia* 2004;47: 943 – 956.
98. Mari A, Ahrén B, Pacini G: Assessment of insulin secretion in relation to insulin resistance. *Current Opinion in Clinical Nutrition & Metabolic Care* 2005;8:529–533.
99. Ferrannini E, Gastaldelli A, Miyazaki Y, et al.: beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. *Journal of Clinical Endocrinology and Metabolism* 2005;90:493–500.
100. Weir GC, Bonner-Weir S: Islets of Langerhans: the puzzle of intraislet interactions and their relevance to diabetes. *Journal of Clinical Investigation* 1990;85:983–987.
101. Scheen AJ, Castillo MJ, Lefebvre PJ: Glucagon-induced plasma C-peptide response in diabetic patients. Influence of body weight and relationship to insulin requirement. *Diabetes & Metabolism* 1996;22:455 – 458.
102. Emoto T, Miyata M, Izukura M, et al.: Simultaneous observation of endocrine and exocrine functions of the pancreas responding to somatostatin in man. *Regulatory Peptides* 1997;68:1 – 8.

103. Park S, Jiang H, Zhang H, Smith RG: Modification of ghrelin receptor signaling by somatostatin receptor-5 regulates insulin release. *PNAS* 2012;109:19003 – 19008.
104. Creutzfeldt W, Lembcke B, Folsch UR, et al.: Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans. *American Journal of Medicine* 1987;82:49 – 54.
105. Damdindorj B, Dezaki K, Kurashina T, et al.: Exogenous and endogenous ghrelin counteracts GLP-1 action to stimulate cAMP signaling and insulin secretion in islet beta-cells. *FEBS Letters* 2012; 586:2555 – 2562.
106. Qader SS, Hakanson R, Rehfeld JF, et al.: Proghrelin-derived peptides influence the secretion of insulin, glucagon, pancreatic polypeptide and somatostatin: a study on isolated islets from mouse and rat pancreas. *Regulatory Peptides* 2008;146:230–237.
107. Egido EM, Hernandez R, Marco J, Silvestre RA: Effect of obestatin on insulin, glucagon and somatostatin secretion in the perfused rat pancreas. *Regulatory Peptides* 2009;152:61–66.
108. Morioka T, Dishinger JF, Reid KR, et al.: Enhanced GLP-1- and sulfonylurea-induced insulin secretion in islets lacking leptin signaling. *Molecular Endocrinology* 2012;26:967–976.
109. Halter JB, Beard JC, Porte D, Jr: Islet function and stress hyperglycemia: plasma glucose and epinephrine interaction. *American Journal of Physiology* 1984;247:E47–52.
110. Lambillotte C, Gilon P, Henquin JC: Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. *Journal of Clinical Investigation* 1997;99:414–423.
111. Rennert NJ, Caprio S, Sherwin RS: Insulin-like growth factor I inhibits glucose-stimulated insulin secretion but does not impair glucose metabolism in normal humans. *Journal of Clinical Endocrinology & Metabolism* 1993;76:804–806.
112. Ahrén B: Autonomic regulation of islet hormone secretion–implications for health and disease. *Diabetologia* 2000;43:393 – 410.
113. Ahrén B, Berggren PO, Rorsman P, et al.: Neuropeptides in the regulation of islet hormone secretion--localization, effects and mode of action. *Advances in Experimental Medicine and Biology* 1991;291:129 – 142.
114. Shimosegawa T, Asakura T, Kashimura J, et al.: Neurons containing gastrin releasing peptide-like immunoreactivity in the human pancreas. *Pancreas* 1993;8:403–412.
115. Ding WG, Kimura H, Fujimura M,etal.: NeuropeptideY and peptide YY immunoreactivities in the pancreas of various vertebrates. *Peptides* 1997;18:1523–1529.
116. Natali A, Gastaldelli A, Galvan AQ, et al.: Effects of acute alpha 2-blockade on insulin action and secretion in humans. *American Journal of Physiology* 1998;274:E57–64.

117. Gram DX, Ahrén B, Nagy I, et al.: Capsaicin-sensitive sensory fibers in the islets of Langerhans contribute to defective insulin secretion in Zucker diabetic rat, an animal model for some aspects of human type 2 diabetes. *European Journal of Neuroscience* 2007; 25:213 – 223.
118. Chandra R, Liddle RA: Modulation of pancreatic exocrine and endocrine secretion. *Current Opinion in Gastroenterology* 2013;29: 517 – 522.
119. Gilliam LK, Palmer JP, Taborsky GJ, Jr: Tyramine-mediated activation of sympathetic nerves inhibits insulin secretion in humans. *Journal of Clinical Endocrinology & Metabolism* 2007;92: 4035 – 4038.
120. Bruce DG, Storlien LH, Furler SM, Chisholm DJ: Cephalic phase metabolic responses in normal weight adults. *Metabolism: Clinical and Experimental* 1987;36:721 – 725.
121. Ahrén B, Holst JJ: The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. *Diabetes* 2001;50:1030 – 1038.
122. Fendler B, Zhang M, Satin L, Bertram R: Synchronization of pancreatic islet oscillations by intrapancreatic ganglia: a modeling study. *Biophysical Journal* 2009;97:722–729.
123. Simon C, Brandenberger G:Ultradianoscillations of insulin secretion in humans. *Diabetes* 2002;51(Suppl 1):S258–261.
124. Ritzel R, Schulte M, Porksen N, et al.: Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. *Diabetes* 2001;50:776–784.
125. Bertram R, Sherman A, Satin LS: Metabolic and electrical oscillations: partners in controlling pulsatile insulin secretion. *American Journal of Physiology—Endocrinology and Metabolism* 2007;293:E890 – 900.
126. Hellman B: Pulsatility of insulin release--a clinically important phenomenon. *Upsala Journal of Medical Sciences* 2009;114: 193 – 205.
127. Porksen N, Grofte T, Greisen J, et al.: Human insulin release processes measured by intraportal sampling. *American Journal of Physiology—Endocrinology and Metabolism* 2002;282:E695–702.
128. Tengholm A, Gylfe E: Oscillatory control of insulin secretion. *Molecular and Cellular Endocrinology* 2009;297:58–72.
129. Lefebvre PJ, Paolisso G, Scheen AJ, Henquin JC: Pulsatility of insulin and glucagon release: physiological significance and pharmacological implications. *Diabetologia* 1987;30:443–452.
130. Saisho Y, Butler AE, Manesso E, et al.: beta-Cell mass and turnover in humans: effects of obesity and aging. *Diabetes Care* 2013;36:111 – 117.
131. Rahier J, Guiot Y, Goebbels RM, et al.: Pancreatic beta-cell mass in European subjects with type 2 diabetes. *Diabetes, Obesity & Metabolism* 2008;10(Suppl 4):32–42.

132. Fritsche A, Stefan N, Hardt E, et al.: A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility. *European Journal of Clinical Investigation* 2000;30:411 – 418.
133. Ward WK, Wallum BJ, Beard JC, et al.: Reduction of glycemic potentiation. Sensitive indicator of beta-cell loss in partially pancreatectomized dogs. *Diabetes* 1988;37:723–729.
134. Robertson RP: Estimation of beta-cell mass by metabolic tests:necessary, but how sufficient? *Diabetes* 2007;56:2420–2424.
135. Blomberg BA, Codreanu I, Cheng G, et al.: Beta-cell imaging: call for evidence-based and scientific approach. *Molecular Imaging and Biology* 2013;15:123–130.
136. Meier JJ, Butler AE, Saisho Y, etal.:Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. *Diabetes* 2008;57:1584–1594.
137. Sorenson RL, Brelje TC: Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. *Hormone and Metabolic Research* 1997;29:301 – 307.
138. Bonnefond A, Froguel P, Vaxillaire M: The emerging genetics of type 2 diabetes. *Trends in Molecular Medicine* 2010;16:407 – 416.
139. Menge BA, Schrader H, Breuer TG, et al.: Metabolic consequences of a 50% partial pancreatectomy in humans. *Diabetologia* 2009;52:306 – 317.
140. Seaquist ER, Robertson RP: Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors. *Journal of Clinical Investigation* 1992;89:1761 – 1766.
141. Meier JJ, Menge BA, Breuer TG, et al.: Functional assessment of pancreatic beta-cell area in humans. *Diabetes* 2009;58:1595 – 1603.
142. Weng J, Li Y, Xu W, et al.: Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. *Lancet* 2008;371:1753 – 1760.
143. Camastra S, Muscelli E, Gastaldelli A, et al.: Long-term effects of bariatric surgery on meal disposal and beta-cell function in diabetic and nondiabetic patients. *Diabetes* 2013;62:3709 – 3717.
144. Mezza T, Muscogiuri G, Sorice GP, et al.: Insulin resistance alters islet morphology in nondiabetic humans. *Diabetes* 2014; 63:994 – 1007.
145. Do OH, Low JT, Gaisano HY, Thorn P: The secretory deficit in islets from db/db mice is mainly due to a loss of responding beta cells. *Diabetologia* 2014;57:1400 – 1409.
146. Meier JJ, Veldhuis JD, Butler PC: Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. *Diabetes* 2005;54:1649 – 1656.

147. Ferrannini E, Wahren J, Faber OK, et al.: Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. *American Journal of Physiology* 1983;244:E517 – 527.
148. Polonsky KS, Given BD, Hirsch L, et al.: Quantitative study of insulin secretion and clearance in normal and obese subjects. *Journal of Clinical Investigation* 1988;81:435 – 441.
149. Guo X, Cui J, Jones MR, et al.: Insulin clearance: confirmation as a highly heritable trait, and genome-wide linkage analysis. *Diabetologia* 2012;55:2183 – 2192.
150. Goodarzi MO, Guo X, Cui J, et al.: Systematic evaluation of validated type 2 diabetes and glycaemic trait loci for association with insulin clearance. *Diabetologia* 2013;56:1282 – 1290.
151. Kotronen A, Vehkavaara S, Seppala-Lindroos A, et al.: Effect of liver fat on insulin clearance. *American Journal of Physiology—Endocrinology and Metabolism* 2007;293:E1709 – 1715.
152. Lorenzo C, Hanley AJ, Wagenknecht LE, et al.: Relationship of insulin sensitivity, insulin secretion, and adiposity with insulin clearance in a multiethnic population: The Insulin Resistance Atherosclerosis Study. *Diabetes Care* 2013;36:101–103.
153. Abdul-Hay SO, Kang D, McBride M, et al.: Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. *PloS ONE* 2011;6:e20818.
154. Carpentier A, Patterson BW, Uffelman KD, et al.: The effect of systemic versus portal insulin delivery in pancreas transplantation on insulin action and VLDL metabolism. *Diabetes* 2001;50:1402 – 1413.
155. Goodarzi MO, Cui J, Chen YD, et al.: Fasting insulin reflects heterogeneous physiological processes: role of insulin clearance. *American Journal of Physiology — Endocrinology and Metabolism* 2011;301:E402 – 408.
156. Eggleston EM, Jahn LA, Barrett EJ: Hyperinsulinemia rapidly increases human muscle microvascular perfusion but fails to increase muscle insulin clearance: evidence that a saturable process mediates muscle insulin uptake. *Diabetes* 2007;56:2958 – 2963.
157. Tamaki M, Fujitani Y, Hara A, et al.: The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance. *Journal of Clinical Investigation* 2013;123:4513 – 4524.
158. Luzi L, Perseghin G, Regalia E, et al.: Metabolic effects of liver transplantation in cirrhotic patients. *Journal of Clinical Investigation* 1997;99:692 – 700.
159. Meier JJ, Holst JJ, Schmidt WE, Nauck MA: Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. *American Journal of Physiology — Endocrinology and Metabolism* 2007;293:E849 – 856.

160. Cordes CM, Bennett RG, Siford GL, Hamel FG: Redox regulation of insulin degradation by insulin-degrading enzyme. *PloS ONE* 2011;6:e18138.
161. Michaliszyn S, Mari A, Lee S, et al.: Beta-cell function, incretin effect and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. *Diabetes* 2014;63(11):3846 – 55.
162. Del Prato S: Loss of early insulin secretion leads to postprandial hyperglycaemia. *Diabetologia* 2003;46(Suppl 1):M2 – 8.
163. Basu A, Alzaid A, Dinneen S, et al.: Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. *Journal of Clinical Investigation* 1996;97:2351 – 2361.
164. Mari A, Ferrannini E: Beta-cell function assessment from modelling of oral tests: an effective approach. *Diabetes, Obesity and Metabolism* 2008;10 (Suppl 4):77 – 87.